Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21043056 | 0.89 | CHRM1 (0.44) | CHRM1GRIN2BGRIN1AAK1 | |
| SCHEMBL16593314 | 0.85 | CHRM1 (0.41) | CHRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16593338 | 0.82 | KDM4E (0.40) | CHRM1BRD4 | |
| SCHEMBL16593304 | 0.78 | NPC1 (0.47) | CHRM1BRD4 | |
| SCHEMBL21043143 | 0.76 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL29391369 | 0.76 | PSMB5 (0.43) | CHRM1GRIN2BRIPK3KCNH2 | |
| SCHEMBL16593254 | 0.74 | CHRM1 (0.80) | CHRM1 | |
| SCHEMBL21042587 | 0.74 | CHRM1 (0.42) | CHRM1GRIN2BCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29393562 | 0.73 | CHRM1 (0.44) | CHRM1 | |
| SCHEMBL29393669 | 0.71 | KDM4E (0.43) | CHRM1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10072005-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-3052496-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072005-B2 | 4-azaindole derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885GRIN2B 65/4885GRIN1 49/4885 |
| US-20160244445-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885GRIN2B 65/4885GRIN1 49/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885GRIN2B 65/4885GRIN1 49/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885GRIN2B 65/4885GRIN1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.